

FEB 25 2004

K 033259

**LIGHT AGE, INC.**

---

**510(k) Summary of Safety and Effectiveness  
Light Age Q-Clear™ Laser**

In accordance with the Safe Medical Devices Act of 1990, 21CFR 807.92, the following is a summary of the safety and effectiveness information on which the substantial equivalence determination is based.

The safety and effectiveness of the Light Age Q-Clear™ Laser derives from a determination of substantial equivalence to the predicate devices listed below.

Applicant: Light Age, Inc.  
500 Apgar Dr.  
Somerset, NJ 08873  
Thomas C. Hauck, Manager of Quality and Process Technology

Date Prepared: December 24, 2003

Model:

Trade Name: Light Age Q-Clear™ Laser  
Common Name: Q-Switched Nd:YAG Laser with Frequency Doubler

Product Code: GEX

Panel: 79

C.F.R. Section: 878.4810

Classification Panel: General & Plastic Surgery

Classification:

Medical Device Class: Regulatory Class II  
Laser Safety Class: Class IV Laser Product

Predicate Devices:

- Palomar Q-YAG™ Nd:YAG Laser System (K023967)
- Medlite™ Q-Switched Nd:YAG Laser (K022709 & K983054)
- Medlite™ C<sup>3</sup> Q-Switched Nd:YAG Laser (K011677)
- Medlite™ C6 Q-Switched Nd:YAG Laser (K014234)
- Spectra-VRM Q-Switched Nd:YAG Laser System (K000317)

Description:

The Light Age Q-Clear™ Laser has a Nd:YAG crystal rod as a lasing medium. Pulsed

# LIGHT AGE, INC.

---

energy is emitted at 1064 nanometers in the near-infrared portion of the spectrum. With the optional frequency doubler installed, a 532nm beam is emitted. The 532nm emission is visible green light. Energy from the laser is delivered directly to the target area via the handpiece, which produces a circular beam on the skin. A red aiming beam is provided to allow the operator to precisely target the treatment area. The Q-Clear™ Laser is equipped with safety features in conformance with 21CFR Part 1040.

## Intended Use:

The Light Age Q-Clear™ Laser is intended for the following uses:

1. For incision, excision, ablation, and vaporization of soft tissue for General Dermatology
2. The 1064nm wavelength is indicated for:
  - Dark ink tattoo removal
  - Treatment of pigmented lesions (particularly Nevus of Ota)
  - Removal or lightening of hair
  - Skin resurfacing with or without adjuvant preparation
  - Treatment of common nevi
3. The 532nm wavelength is indicated for:
  - Removal of light ink (red, tan, purple and orange) tattoos
  - Treatment of common nevi
  - Treatment of café-au-lait spots
  - Treatment of seborrheic keratoses
  - Treatment of vascular lesions, including facial and leg veins, telangiectasias, angiomas, hemangiomas, port wine stains, and most pigmented lesions (e.g. lentigines, and ephelides)

## Safety and Effectiveness:

The Light Age Q-Clear™ Laser has the same wavelengths, the same spot size, the same principle of operation, essentially the same fluence levels, and the same intended use as the predicate devices. The Light Age Q-Clear™ Laser does not raise new questions of safety or efficacy, and is substantially equivalent to the predicate devices.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

FEB 25 2004

Mr. Thomas C. Hauck  
Manager of Quality and Process Technology  
Light Age, Inc.  
500 Apgar Drive  
Somerset, New Jersey 08873

Re: K033259

Trade/Device Name: Light Age Q-Clear™ Laser  
Regulation Number: 21 CFR 878.4810  
Regulation Name: Laser surgical instrument for use in general and  
plastic surgery and in dermatology  
Regulatory Class: II  
Product Code: GEX  
Dated: January 20, 2004  
Received: January 20, 2004

Dear Mr. Hauck:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 - Mr. Thomas C. Hauck

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read "Celia M. Witten". The signature is written in a cursive style and is positioned to the left of the typed name.

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative  
and Neurological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

# LIGHT AGE, INC.

---

## Indications for Use

510(k) Number (if known): K033259

Device Name: Light Age Q-Clear™ Laser

Indications for Use:

The Light Age Q-Clear™ Laser is indicated for the following uses:

1. For incision, excision, ablation, and vaporization of soft tissue for General Dermatology
2. The 1064nm wavelength is indicated for:
  - Dark ink tattoo removal
  - Removal of pigmented lesions (particularly Nevus of Ota)
  - Removal or lightening of hair
  - Skin resurfacing with or without adjuvant preparation
  - Treatment of common nevi
3. The 532nm wavelength is indicated for:
  - Removal of light ink (red, tan, purple and orange) tattoos
  - Treatment of common nevi
  - Treatment of café-au-lait spots
  - Treatment of seborrheic keratoses
  - Treatment of vascular lesions, including facial and leg veins, telangiectasias, angiomas, hemangiomas, port wine stains, and most pigmented lesions (e.g. lentigines, and ephelides)

Prescription Use  X   
(Part 21 CFR 801 Subpart D)


AND/OR

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
\_\_\_\_\_  
(Division Sign-Off)

**Division of General, Restorative,  
and Neurological Devices**

Page 1 of 1

(Posted November 13, 2003)

**510(k) Number** K033259